Insider Trading Alert - TRS, CW, UMBF And OPK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Nov. 29, 2013, 50 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $630.00 to $1,172,700,000.00.

Highlighted Stocks Traded by Insiders:

TriMas Corporation (TRS) - FREE Research Report

Tredwell Daniel P who is Director at TriMas Corporation sold 300,000 shares at $36.60 on Nov. 29, 2013. Following this transaction, the Director owned 274,814 shares meaning that the stake was reduced by 52.19% with the 300,000 share transaction.

Sherbin Joshua A who is Vice President & Secretary at TriMas Corporation sold 4,384 shares at $36.55 on Nov. 29, 2013. Following this transaction, the Vice President & Secretary owned 50,297 shares meaning that the stake was reduced by 8.02% with the 4,384 share transaction.

The shares most recently traded at $36.65, up $0.10, or 0.27% since the insider transaction. Historical insider transactions for TriMas Corporation go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 100
  • 12-Week # shares sold: 5,000
  • 24-Week # shares bought: 100
  • 24-Week # shares sold: 60,500

The average volume for TriMas Corporation has been 337,300 shares per day over the past 30 days. TriMas Corporation has a market cap of $1.6 billion and is part of the industrial goods sector and industrial industry. Shares are up 30.61% year to date as of the close of trading on Friday.

TriMas Corporation designs, manufactures, and distributes various products for commercial, industrial, and consumer markets worldwide. The company has a P/E ratio of 27.9. Currently there are 4 analysts that rate TriMas Corporation a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on TRS - FREE

TheStreet Quant Ratings rates TriMas Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full TriMas Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Curtiss-Wright Corporation (CW) - FREE Research Report

Denton Michael J who is Vice President and Secretary at Curtiss-Wright Corporation sold 2,400 shares at $52.07 on Nov. 29, 2013. Following this transaction, the Vice President and Secretary owned 30,671 shares meaning that the stake was reduced by 7.26% with the 2,400 share transaction.

The shares most recently traded at $52.32, up $0.25, or 0.48% since the insider transaction. Historical insider transactions for Curtiss-Wright Corporation go as follows:

  • 4-Week # shares sold: 950
  • 12-Week # shares sold: 950
  • 24-Week # shares sold: 950

The average volume for Curtiss-Wright Corporation has been 216,100 shares per day over the past 30 days. Curtiss-Wright Corporation has a market cap of $2.5 billion and is part of the technology sector and electronics industry. Shares are up 60.1% year to date as of the close of trading on Friday.

Curtiss-Wright Corporation provides engineered products and services to the defense, power generation, oil and gas, commercial aerospace, and general industrial markets worldwide. It operates through three segments: Flow Control, Controls, and Surface Technologies. The stock currently has a dividend yield of 0.76%. The company has a P/E ratio of 19.4. Currently there are 3 analysts that rate Curtiss-Wright Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CW - FREE

TheStreet Quant Ratings rates Curtiss-Wright Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Curtiss-Wright Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

UMB Financial Corporation (UMBF) - FREE Research Report

Rilinger Dennis R who is EVP and General Counsel at UMB Financial Corporation sold 2,501 shares at $64.24 on Nov. 29, 2013. Following this transaction, the EVP and General Counsel owned 13,064 shares meaning that the stake was reduced by 16.07% with the 2,501 share transaction.

The shares most recently traded at $64.19, down $0.05, or 0.08% since the insider transaction. Historical insider transactions for UMB Financial Corporation go as follows:

  • 4-Week # shares bought: 146
  • 4-Week # shares sold: 6,474
  • 12-Week # shares bought: 146
  • 12-Week # shares sold: 6,474
  • 24-Week # shares bought: 274
  • 24-Week # shares sold: 17,732

The average volume for UMB Financial Corporation has been 278,700 shares per day over the past 30 days. UMB Financial Corporation has a market cap of $2.9 billion and is part of the financial sector and banking industry. Shares are up 47.15% year to date as of the close of trading on Friday.

UMB Financial Corporation, through its subsidiaries, offers various banking and other financial services in the United States. The company operates through four segments: Bank, Payment Solutions, Institutional Investment Management, and Asset Servicing. The stock currently has a dividend yield of 1.4%. The company has a P/E ratio of 21.7. Currently there is 1 analyst that rates UMB Financial Corporation a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UMBF - FREE

TheStreet Quant Ratings rates UMB Financial Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full UMB Financial Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 10,900 shares at $10.31 on Nov. 29, 2013. Following this transaction, the CEO & Chairman owned 137.2 million shares meaning that the stake was reduced by 0.01% with the 10,900 share transaction.

The shares most recently traded at $10.71, up $0.40, or 3.72% since the insider transaction.

The average volume for Opko Health has been 5.0 million shares per day over the past 30 days. Opko Health has a market cap of $4.2 billion and is part of the health care sector and health services industry. Shares are up 115.38% year to date as of the close of trading on Friday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Pound Slides as Inflation Slows, Doubts Grow Over Bank of England Rate Hikes

Pound Slides as Inflation Slows, Doubts Grow Over Bank of England Rate Hikes

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start